Systematic evaluation of SARS-CoV-2 spike protein derived peptides for diagnosis of COVID-19 patients

3

Yang Li^{1, #}, Dan-yun Lai^{1, #}, Qing Lei^{2, #}, Zhao-wei Xu^{1,7, #}, Hongyan Hou^{3,#}, Lingyun Chen⁴, Jiaoxiang Wu⁵, Yan Ren⁶, Ming-liang Ma¹, Bo Zhang³, Hong Chen¹, Caizheng Yu⁸, Jun-biao Xue¹, Yun-xiao Zheng¹, Xue-ning Wang¹, He-wei Jiang¹, Hai-nan Zhang¹, Huan Qi¹, Shu-juan Guo¹, Yandi Zhang², Xiaosong Lin², Zongjie Yao², Pengfei Pang⁹ Dawei Shi¹⁰, Wei Wang¹¹, Xiao Yang¹², Jie Zhou¹¹, Huiming Sheng⁵, Ziyong Sun³, Hong Shan^{9, *}, Feng Wang^{3, *}, Xionglin Fan^{2, *}, Sheng-ce Tao^{1, *}

- 10 11
- ¹Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry
- 13 of Education), Shanghai Jiao Tong University, Shanghai, China
- 14 ²Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong
- 15 University of Science and Technology, Wuhan, China
- 16 ³Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong
- 17 University of Science and Technology, Wuhan, China
- ⁴BGI Education Center, University of Chinese Academy of Sciences, Shenzhen 518083, China
- 19 ⁵Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 20 ⁶BGI-Shenzhen, Shenzhen, 518083, China
- 21 ⁷Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education,
- 22 School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China
- 23 ⁸Department of Public Health, Tongji Hospital, Tongji Medical College, Huazhong University of
- 24 Science and Technology, Wuhan, China
- 25 ⁹Center for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University,
- 26 Zhuhai, 519000, China
- ²⁷ ¹⁰National Institutes for Food and Drug Control, Beijing, 100050, China
- 28 ¹¹Foshan Fourth People's Hospital, Foshan 528000, China
- 29 ¹²Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences,
- 30 Beijing, 100101, China.
- [#] These authors contribute equally to this work.
- 32
- 33 *Corresponding Authors, e-mail: taosc@sjtu.edu.cn (S.-C. Tao), xlfan@hust.edu.cn (X.-L. Fan),
- 34 fengwang@tjh.tjmu.edu.cn (F. W.) and <u>shanhong@mail.sysu.edu.cn</u> (H. S.)

35 One Sentence Summary:

Eight S protein-derived peptides, particularly S2-78 (aa 1148-1159), are of high performance for diagnosis of COVID-19 as well as discrimination of other coronaviruses.

38 Abstract

Serological test plays an essential role in monitoring and combating COVID-19 39 40 pandemic. Recombinant spike protein (S protein), especially S1 protein is one of the major reagents for serological tests. However, the high cost in production of S protein, 41 42 and the possible cross-reactivity with other human coronaviruses poses unneglectable challenges. Taking advantage of a peptide microarray of full spike protein coverage, we 43 analyzed 2,434 sera from 858 COVID-19 patients, sera from 63 asymptomatic patients 44 and 610 controls collected from multiple clinical centers. Based on the results of the 45 peptide microarray, we identified several S protein derived 12-mer peptides that have 46 47 high diagnosis performance. Particularly, for monitoring IgG response, one peptide (aa 1148-1159 or S2-78) has a comparable sensitivity (95.5%, 95% CI 93.7-96.9%) and 48 specificity (96.7%, 95% CI 94.8-98.0%) to that of S1 protein for detection of both 49 COVID-19 patients and asymptomatic infections. Furthermore, the performance of S2-78 50 IgG for diagnosis was successfully validated by ELISA with an independent sample 51 cohort. By combining S2-78/S1 with other peptides, a two-step strategy was proposed to 52 ensure both the sensitivity and specificity of S protein based serological assay. The 53 54 peptide/s identified in this study could be applied independently or in combination with 55 S1 protein for accurate, affordable, and accessible COVID-19 diagnosis.

57 COVID-19 is caused by SARS-CoV-2[1,2] and is a global pandemic. By August 7, 2020, 18,982,658 712,266 58 cases were diagnosed and lives were claimed 59 (https://coronavirus.jhu.edu/map.html)[3]. To put the pandemic under control, one of the essential options is to perform fast, reliable and affordable diagnosis. Although nucleic 60 acid test (NAT) is the reference standard for diagnosing COVID-19 with high sensitivity 61 62 and accuracy, however, false negative results were commonly observed[4,5]. The immunological/ serological test, for example, monitoring the SARS-CoV-2 specific IgG 63 and IgM responses, provides important information to improve the accuracy of 64 diagnosis[4,5]. In addition, serological test is suitable for population screening in high 65 risk regions or among close-contact people, as well as surveillance of the pandemic 66 spreading or assess the infection rate of general population[6-8]. Moreover, antibody 67 68 response is reported to associated with disease severity or clinical outcomes[9,10].

69

S protein is the preferential antigen for serological assay. The key reagent of the S 70 71 protein based serological assay is the recombinant protein. However, the production of 72 the S protein is difficult and costly[11]. The inconsistency among different manufacturers or even batches might contribute to the variability of commercial assays with the same 73 74 antigen[7,12]. Limited production capacity and high cost of recombinant protein preparation is the bottleneck, particularly for remote regions or poor countries. In 75 76 addition, it should be concerned that the cross-reactivity of infections of other human coronaviruses may cause false positive results, especially for those four common cold 77 78 causing coronaviruses, i.e., HCoV-OC43, HKU1, NL63 and 229E, which are circulating in population[4,11,13]. It was reported that S1, compared with full length S protein, 79 80 exhibit less cross-reactivity due to the less similarity of S1 subunit among the human coronaviruses than that of S2[4]. To develop highly specific serological test, more efforts 81 are needed to identify sections of S protein that are highly immunogenic and less 82 homologous to other related coronaviruses[6,11]. 83

84

Spike protein derived peptides that can elicit antibodies in COVID-19 patients has been reported in several studies[14–16], including one of our previous work on epitope mapping with a small sample cohort[17]. For instance, antibody against S2-78 (aa

88 1148-1159) and S2-22 (aa 812-823) have high positive rates in COVID-19 patients. However, whether those peptides are suitable for diagnosis is still unknown. Herein, to 89 90 fully evaluate the diagnostic value of the S protein derived peptides, a total of four cohorts of sera, consisted of 2,434 sera from 858 COVID-19 patients, sera from 63 91 asymptomatic patients and 610 controls were used. Eight peptides were verified to have 92 high potential for diagnosis, particularly, one peptide, S2-78 has a comparable diagnosis 93 performance as that of S1 protein for COVID-19 patients and asymptomatic infections. 94 By combining S2-78 IgG/S1 IgG with other peptide/s, we purposed a two-step strategy 95 that can ensure both sensitive and specific diagnosis for COVID-19. 96

97

98 **Results**

99

100 Four independent cohorts of samples were collected and designed

101 To fully evaluate the diagnostic potential of the spike derived peptides, sera from four cohorts of COVID-19 patients and controls from multiple medical centers of China were 102 103 collected (Table 1). 1) Cohort 1 consists of 55 sera from convalescent COVID-19 patients and 18 controls[17]; 2) Cohort 2 includes 2,360 sera from 784 in-hospital 104 COVID-19 patients and 542 sera from a variety of controls. To accurately evaluate the 105 peptides for diagnosis, for each patient, one serum sample that collected at least 21 days 106 107 after onset of symptoms was selected according to the suggestion of WHO (World Health Organization) for antibody laboratory test[18]. As a result, in total, 729 sera were selected. 108 109 The control groups include two types of samples. The first type is sera collected from 110 hospitals, including sera from healthy people (n=92), upper respiratory infections (URI, 111 n=104), patients with autoimmune diseases (AID, n=120), lung cancer patients (n=41) and patients with other diseases (n=112) that consist of cardiovascular or cerebrovascular 112 113 diseases (34.2%), diabetes (9%), non-lung cancers (7.2%) and others. The second type is negative references provided by National Institutes for Food and Drug Control, including 114 N11-N25 of National Reference Panel for 2019-nCoV (SARS-CoV-2) IgG Antibody 115 Detection Kit (370096-202001) and other identified controls. 3) Cohort 3 includes 19 116 117 COVID-19 patients from another hospital and 50 healthy controls. 4) Cohort 4 consists of asymptomatic patients defined as positive either on NAT (nucleic acid test) or antibody 118

119 test conducted by a commercial assay, and with a SARS-CoV-2 exposure history (see

120 methods).

121

122 Peptide S2-78 and several other peptides exhibit high diagnostic values

To identify which section of S protein has diagnostic value, it is necessary to survey the 123 entire protein on a systematic way. We took advantage of a previously constructed 124 peptide microarray which has full coverage of S protein[17], analyzed 55 convalescent 125 sera of COVID-19 patients along with 18 control sera (Cohort 1, Table 1). Overall, 126 significant bindings of both IgG and IgM were observed in patient group, while the 127 signals were low in the control group (Fig. 1a). Several peptides, e. g., S2-78 and S1-93 128 129 exhibit strong IgG antibody bindings and high response frequencies in patients, we define these peptides as "significant" peptides, these peptides may have diagnostic values (Fig. 130 **1b**). To test whether the peptide specific IgG antibody responses are concentration 131 dependent, 3x serially diluted peptides (0.9, 0.3 and 0.1 mg/mL) were printed and 132 133 immobilized on the microarray. As expected, the averaged signals of the patient group, 134 but not the control group, are proportional to the concentrations of the peptides (**Fig. 1c**).

135 To extensively evaluate the peptides for diagnostic application, a larger cohort (Cohort 2, **Table 1**) of samples were screened by a revised peptide microarray that contains only 136 one peptide concentration (0.3 mg/mL) for high-throughput analysis. To ensure the data 137 generated from different microarrays are comparable, we prepared a positive reference 138 139 sample by pooling 50 randomly selected patient sera. This reference sample was then 140 tested on all the microarrays for normalization (see **methods**). Consistent results were 141 achieved for most of the peptides. AUC (area under curve) values of IgG or IgM for each peptide were calculated. Eight peptides, *i. e.*, S2-78, S1-97, S1-93, S1-101, S1-111, S2-97, 142 S1-105 and S2-22 are of high performance, the AUCs of IgG or IgM against these 143 peptides for both Cohort 1 and 2 are above 0.85. Specifically, for Cohort 2 the AUC 144 145 values with 95% CI (confidential intervals) for S2-78, S1-97, S1-93, S1-101, S1-111, S2-97, S1-105 and S2-22 were 0.99 (0.986-0.995), 0.954 (0.942-0.965), 0.934 146 (0.92-0.948), 0.932, (0.917-0.947), 0.929, (0.915-0.943), 0.922, (0.907-0.938), 0.909147 (0.893-0.926), and 0.866 (0.846-0.886), respectively (Fig. 2a). For IgM, only S2-78 has a 148 AUC >0.85, i. e., 0.953 (0.941-0.964) (Fig. 2a). As expected, IgG and IgM for both N 149

150 protein and S1 protein exhibited high performance. We further examined the antibody responses in different groups for each peptide (Fig. 2b-e, Fig. S1). Consistently, signals 151 152 for COVID-19 group are significantly higher than that of the negative samples in all groups. It is noted that the signal intensity for S1 IgG is generally higher than that of any 153 single peptide in the group of COVID-19 patients, this may because there are multiple 154 antibody binding sites on S1 protein. However, slightly higher signal is also observed in 155 control group for protein antigens, demonstrating non-specific binding while it is largely 156 eliminated for synthetic peptides. It is suggested that more sensitive detection platforms 157 or higher antigen concentration might improve the performance of peptides for diagnosis. 158

159

160 *The diagnostic performance of S2-78 IgG is comparable to that of S1 IgG for COVID-19* 161 *patients*

We next focused on S2-78, the peptide of best performance for detection. Optimal 162 Youden index of ROC (receiver operating characteristic) curve was used to set the cutoff 163 value. The specificity, sensitivity and overall accuracy (95% CI) of S2-78 IgG for 164 165 detection of COVID-19 are 96.7 (94.8-98.0%), 95.5% (93.7-96.9%) and 96% (94.8-97%), respectively, which are slightly lower than that of S1 IgG (Table 2). Since serological 166 167 test is essential for population screening, we calculated the PPV (positive predict value) and NPV (negative predict value) of two assumed prevalence rates. One is 0.04 for 168 169 general population originated from the situations of Wuhan, China[19] and Netherlands[20]. The other is 0.5 for a high risk population[7]. For prevalence rate of 0.5, 170 171 both PPV and NPV of S2-78 IgG is similar to that of S1 IgG, however, for prevalence rate of 0.04, the PPV is only 54.7%, although the NPV is extremely high, suggesting the 172 173 antibody detection of S2-78 could effectively exclude negative ones but may generate high false positive rate at low rate. However, for low prevalence rate, since the number of 174 real positive are very low, it might be acceptable to perform additional test by using other 175 antigens to improve the overall performance. 176

177

We next investigated the consistency between S1 IgG and S2-78 IgG (**Fig. 3a, b**). The overall consistencies for COVID-19 group and Control group are 96.3% and 96.7%, respectively. Interestingly, there are eight samples from COVID-19 patients are negative

181 for S1 IgG but positive for S2-78 IgG, suggesting it will be of diagnostic value to combine S2-78 and S1. It is known that the immune response may correlate to some key 182 183 clinical parameters, such as gender, disease severity, age and the final outcome [5,9]. To test whether the positive rate of S2-78 IgG is associated with these clinical parameters, 184 we analyzed the detection sensitivities among subgroups, *i. e.*, male vs. female, ≥ 60 vs. 185 <60 for age, severe vs. non-severe cases and survivor vs. non- survivor with critical 186 diseases. Similar to that of S1 IgG (Fig. S2a), no significant difference was observed in 187 all these subgroups. 188

189

Virus specific antibodies would persistently increase and usually conduct 190 seroconversion within one or two weeks after symptom onset, and the portion of patients 191 192 with positive antibodies reach $\sim 100\%$ after two or three weeks[21,22]. To test whether S2-78 IgG is suitable to detect the dynamic change of antibody response, we analyzed the 193 positive rates at different time points after the onset of symptoms. Expectedly, the 194 positive rate of S2-78 IgG continuously increased and reach the plateau about three 195 196 weeks after onset, which is similar as S1 and N IgG (Fig. 3d). Similar trends were observed for S2-78 IgM (Fig. 3e) and IgG antibodies against other peptides (Fig. S2b). 197 198 These observations suggest that the antibodies against S2-78 and other peptides could be applied for monitoring virus specific antibody dynamics. 199

200

201 The diagnostic performance of S2-78 IgG is comparable to that of S1 IgG for 202 asymptomatic infections

Monitoring of asymptomatic infections is essential to put SARS-CoV-2 infection under 203 204 control. It is thought that asymptomatic infection usually has a weak immune response[23]. To test whether S2-78 IgG could be used for detection of asymptomatic 205 infection, we analyzed 63 asymptomatic patients (Cohort 4, **Table 1**) defined as positive 206 either in NAT test or antibody test conducted by a commercial assay (see **methods**) but 207 208 without obvious symptom. Four subgroups were divided according to positive or not for 209 NAT, IgG or IgM[24]. It was shown that for S1 IgG and S2-78 IgG, all samples (n=4) of IgG⁻ group were negative, while of the 59 IgG⁺ asymptomatic infections, 47 and 45 were 210 positive for S1 IgG and S2-78 IgG, respectively. (Fig 4a, b). The consistency between S1 211

IgG and S2-78 IgG was also high (93.7%). The contradictory results in IgG^+ group between our data and the commercial assay may due to the differences of antigens involved. S and N recombinant proteins are used for the commercial assay, for which slightly lower specificity is common[7]. Overall, these results demonstrate the diagnostic and screening value of S2-78 IgG for asymptomatic infections.

217

218 The diagnostic value of S2-78 IgG was validated by ELISA

ELISA (enzyme linked immunosorbent assay) is common for commercial SARS-CoV-2 219 antibody assays[8,25]. To verify the efficacy and applicability of S2-78 IgG, we 220 established an ELISA assay. Firstly, to test the consistency of the peptide microarray and 221 ELISA, we randomly selected 31 sera from COVID-19 patients of Cohort 1 and tested by 222 ELISA. High consistency was achieved with a Pearson correlation of 0.926 (Fig. 5a), 223 demonstrating the validity of the microarray results. To further validate the performance 224 225 of S2-78 IgG, we screened another independent cohort of samples collected from a different medical center (Cohort 3, Table 1). As expected, high performance of S2-78 226 227 IgG for specific detection of COVID-19 was achieved by ELISA (Fig. 5b, c).

228

A two-step strategy by combining S2-78 and other peptides for specific detection of
 SARS-CoV-2 infections

232 Because of the highly homologous genomes among human coronaviruses, one 233 unneglectable risk for antibody based diagnosis of SARS-CoV-2 infection is the possible 234 cross-reactivity with other coronaviruses, especially for those common cold causing 235 coronaviruses, *i. e.*, HCoV-OC43, HKU1, NL63 and 229E. The protein sequences of S 236 protein among those viruses are of high similarity, selection of sections of S protein that are unique for SARS-CoV-2 is important for diagnosis[11,13]. To investigate whether the 237 identified peptides are specific to SARS-CoV-2, we performed homology analysis among 238 SARS-CoV-2 and 6 other coronaviruses (Extended data Fig 3). High homologies were 239 observed for S2-78 and S2-22, suggesting they alone may not suitable for specific 240 241 detection of SARS-Cov-2 infection. In contrast, other peptides, *i. e.*, S1-93, 97,101,105,111 and S2-97, exhibit low similarities with other coronaviruses, particularly 242 the four coronaviruses that cause common cold in human, suggesting they could be 243

applied for specifically detection of SARS-Cov-2 infection. S1-97 with the best 244 performance among these peptides was selected for further investigation. Considering the 245 246 relatively low sensitivity (86.2%) of S1-97 IgG (Fig. 2, Fig. S4), we proposed a two-step strategy by combining S1-97 IgG and S2-78 IgG for detection (Fig. 6a). To simplify this 247 strategy, there are three assumptions: 1) S2-78 IgG can detect the infection of 248 SARS-CoV-2 and related coronaviruses with the same sensitivity (95.5%) and generates 249 a false positive rate of 3.3% (1-speficicity, 1-96.7%) for healthy and patients of other 250 diseases; 2) S1-97 IgG can specially detect SARS-CoV-2 infection with 86.2% sensitivity 251 and no cross-reactivity with related coronaviruses, so it would generate a false positive 252 rate of 6.8% (1-speficicity, 1-93.2%) for the infection of related coronaviruses, healthy 253 control and patients with other diseases; 3) The positive rate of S2-78 IgG and S1-97 IgG 254 in each group is independent to each other. According to the two-step strategy (Fig. 6a), 255 for any given sample, the first step is to detect S2-78 IgG; For the positive ones, the 256 second step is to detect S1-97 IgG. The samples positive for both S2-78 and S1-97 are 257 defined as final positive, while the samples negative for either one is defined as negative. 258 259 As a result, the sensitivity for SARS-CoV-2 infection detection would be 82.3%, the specificity for related coronavirus infections would be 93.5% (specificity 1), and the 260 261 specificity for control group would be 99.8% (specificity 2). To further improve the performance of the two-step strategy, a panel (Panel-A) of peptides was composed by 262 263 bivariate regression analysis based on the specificity of each peptide to SARS-CoV-2. The linear function for Panel-A is $y = 0.014 \times x_1 + 0.02 \times x_2 - 0.003 \times x_3 + 0.006 \times x_4 + 2.593$, 264 265 where y represents signals of Panel-A and x_1 , x_2 , x_3 , x_4 represents the signals of IgG against S1-93, 97, 101 and 105, respectively. The sensitivity and specificity of Panel A, 266 267 based on the data generated from Cohort 2, is 88.3% and 96.7%, respectively (Fig. 6b, c). 268 Follow the two-way strategy by combining S2-78 IgG and Panel-A, the final sensitivity for the detection of SARS-CoV-2 infection, specificity for related coronavirus infection 269 (specificity 1), and the specificity for control group (specificity 2) are 84.3%, 96.8% and 270 271 99.9%, respectively (Fig. 6d). When S1 protein and Panel-A are combined, the final 272 sensitivity for the detection of SARS-CoV-2 infection, specificity for related coronavirus infection (specificity 1), and the specificity for control group (specificity 2) are 85.3%, 273 96.8% and 99.99%, respectively (Fig. S4b). These results demonstrate that combination 274

of human coronavirus conserved peptides or S1 protein and other SARS-CoV-2 specific
peptides ("significant" peptides) enable specific detection of SARS-CoV-2 infection with
a high specificity and acceptable sensitivity.

278

279 **Discussion**

In this study, we took advantage of a peptide microarray of full S protein coverage 280 [17,26], analyzed 2,434 sera from 858 COVID-19 patients, sera from 63 asymptomatic 281 282 patients and 610 controls collected from multiple medical centers. We identified eight 12-mer peptides ("significant" peptides) which exhibit high diagnostic values as antigens 283 to detect SARS-CoV-2 specific IgG or IgM. Among the "significant" peptides, S2-78 284 IgG has a comparable diagnosis performance to that of S1 protein for the detection of 285 COVID-19 and asymptomatic infections, suggesting S2-78 has the potential for 286 287 serological prevalence investigation. By combining S2-78 and other "significant" peptides of low homologous among common human coronaviruses, we purposed a 288 289 two-step strategy for accurate and affordable detection of SARS-CoV-2 infection.

290

291 Serological test plays an important role in diagnosis and monitoring of COVID-19. Recombinant proteins, particular S1, is one of the key reagents to build immunoassay for 292 293 detecting SARS-CoV-2 IgG, IgM or IgA. However, expressing S1 protein in the right conformation is usually difficult, and in some cases, the antibodies that recognize 294 295 membrane spike protein are unable to bind recombinant S protein[27]. Moreover, the inconsistency of the proteins from different manufacturers and even different batches 296 from the same manufacturer may result in high variation. High cost and insufficient 297 capacity to produce enough amount of high quality recombinant S1 protein limits the 298 299 accessibility of the immunoassay in poor or remote regions around the world. Alternatively, peptide-based immunoassay provides a superior choice to S1 protein 300 assays. The reasons are as follows: 1) The peptide synthesis could be easily scaled up 301 302 when required. A large amount of peptide could be easily synthesized within a very short period of time, if necessary, the peptide could be synthesized in a GMP facility; 2) The 303 consistency and purity of peptide synthesis is high, there is almost no batch-to-batch 304

variation; 3) Peptide is very stable, as reagent, it could be easily stored and transported; 4)
 The cost of peptide is about 2-3 magnitude lower than that of S1 protein.

307

We identified S2-78 as a candidate of high diagnostic value. Applying large cohorts of 308 COVID-19 patients and a variety types of controls, we comprehensively verified S2-78 309 310 IgG as a good candidate for diagnosis of COVID-19, with comparable specificity and sensitivity to that of S1 IgG. Expectedly, we found that the overall consistency of S2-78 311 IgG and S1 IgG is high, suggesting S2-78 has the potential to replace S1 protein. It is 312 notable that, the signal intensity level of S2-78 IgG is lower than that of S1 IgG, which is 313 reasonable since there are multiple sites on S1 protein that could be recognized by 314 antibodies in COVID-19 sera. However, because it is hard to ensure extremely high 315 316 purity when purifying recombinant proteins, the background of S1 IgG for control group is also higher than that of peptides. These results imply the sensitivity of S2-78 IgG might 317 be further evaluated when raise the antigen concentration or adopt a more sensitive 318 platform for detection, such as electrochemical platform or single-molecule detection 319 320 technologies [28,29]. Indeed, we also performed S1 based ELISA assay by a commercial kit with the same set of samples, the overall performance of S2-78 IgG based ELISA is 321 322 comparable to that of the commercial kits (data not shown).

323

324 Immunoassay is the major tool to assess the extent of virus circulation in population and the likelihood of protection against re-infection by screening population to identify 325 326 infected individuals without clinical symptoms[7,12,19]. We verified that S2-78 IgG could be applied to detect asymptomatic infections with a comparable sensitivity and 327 328 specificity with S1 IgG, though these individuals are thought to have weaker immune responses[23]. We assessed PPV and NPV for two prevalence rates, *i. e.*, 0.04 and 0.5. 329 For 0.04, the PPV is 54.7% and NPV is 99.8%, indicating a high false positive rate, while 330 it can effectively and accurately exclude the negative ones. Due to the small number of 331 332 positive cases under this circumstance, one possible solution is to re-test the suspected 333 samples by additional assays. Moreover, to meet the requirement of population-wide application, the performance of S2-78 might be improved by optimizing the parameters 334 or adoption of other platforms. 335

336

S protein shares high sequence similarities with other seasonal circulated human 337 338 coronaviruses. Theoretically, cross-reactivity may exist when S/S1 is applied as antigen for immunological test, thus cause false positive. It is thus necessary to pinpoint specific 339 regions/ sites of SARS-CoV-2 S protein and eliminate the potential cross-reactivity. 340 Selection of peptides with high antibody responses and low sequence similarities with 341 other coronaviruses will improve the performance of diagnosis. Among the identified 342 peptides, except S2-78 and S2-22, other peptides are very distinct to the four circulating 343 human coronaviruses, implying that they could be served as the specific antigen to 344 eliminate the potential cross-activity. However, these peptides exhibit slightly lower 345 sensitivity and specificity. To take advantage of these "significant" peptides, we proposed 346 347 a two-step strategy that combine S2-78 with other significant peptide/s to discriminate SARS-CoV-2 from related infections as well as non-infections. This study could be 348 further strengthened by testing sera collected from the infections of common human 349 coronaviruses, i. e., HCoV-OC43, HKU1, NL63 and 229E. 350

351

In summary, we identified and verified eight peptides derived from S protein that exhibit high diagnostic values. These peptides might be used in different circumstances alone or in combination as candidates to build immunoassay/s for monitoring COVID-19. In comparison to the current protein based immunoassays, the peptide based assays will be highly affordable and accessible.

357

358 Materials and Methods

359 *Patients and samples*

The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (ITJ-C20200128), Institutional Ethics Review Committee of Foshan Fourth Hospital, Foshan, China (202005) and the Ethical Committee of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China (K14-2). Written informed consent was obtained from all participants enrolled in this study. COVID-19 patients were hospitalized and

received treatment in multiple medical center during the period from 25 January 2020 366 and 28 April 2020. Sera of the control group from healthy donors, lung cancer patients, 367 368 patients with autoimmune diseases were collected from Ruijin Hospital, Shanghai, China or Tongren Hospital, Shanghai, China. The negative reference samples were from 369 National Institutes for Food and Drug Control. Sera of 63 asymptomatic patients were 370 also from Tongji Hospital, Wuhan. The IgM and IgG antibodies against recombinant 371 nucleoprotein and spike protein of SARS-CoV-2 in sera of these patients were detected 372 by a commercial kit (YHLO Biotech, Shenzhen, China). According to the instruction of 373 the kit, the antibody level ≥ 10 AU/ mL is positive, and < 10 AU/mL is negative. All the 374 samples were stored at -80°C until use. 375

376

377 Peptide synthesis and conjugation with BSA

The N-terminal amidated peptides were synthesized by GL Biochem, Ltd. (Shanghai, 378 379 China). Each peptide was individually conjugated with BSA using Sulfo-SMCC (Thermo 380 Fisher Scientific, MA, USA) according to the manufacture's instruction. Briefly, BSA was activated by Sulfo-SMCC in a molar ratio of 1: 30, followed by dialysis in PBS 381 382 buffer. The peptide with cysteine was added in a w/w ratio of 1:1 and incubated for 2 h, followed by dialysis in PBS to remove free peptides. A few conjugates were randomly 383 384 selected for examination by SDS-PAGE. For the conjugates of biotin-BSA-peptide, before conjugation, BSA was labelled with biotin by using NHS-LC-Biotin reagent 385 386 (Thermo Fisher Scientific, MA, USA) with a molar ratio of 1: 5, and then activated by Sulfo-SMCC. 387

388

389 Peptide microarray fabrication

The peptide-BSA conjugates as well as S1 protein, RBD protein and N protein of SARS-CoV-2, along with the negative (BSA) and positive controls (anti-Human IgG and IgM antibody), were printed in triplicate on PATH substrate slide (Grace Bio-Labs, Oregon, USA) to generate identical arrays in a 1 x 7 (for the peptide microarray with three concentrations) or 2 x 7 subarray format (for the peptide microarray with one

concentration) using Super Marathon printer (Arrayjet, UK). The microarrays were stored
at -80°C until use.

397

398 Microarray-based serum analysis

399 A 7 or 14-chamber rubber gasket was mounted onto each slide to create individual chambers for the 7 or 14 identical subarrays. The microarray was used for serum 400 401 profiling as described previously with minor modifications[30]. Briefly, the arrays stored 402 at -80°C were warmed to room temperature and then incubated in blocking buffer (3% 403 BSA in 1×PBS buffer with 0.1% Tween 20) for 3 h. A total of 400 μ L for 7-subarray format or 200 µL 14-subarray format of diluted sera or antibodies was incubated with 404 405 each subarray for 2 h. The sera were diluted at 1:200 for most samples and for competition experiment, free peptides were added at a concentration of 0.25 mg/mL. For 406 407 the enriched antibodies, 0.1-0.5 μ g antibodies were included in 200 μ L incubation buffer. The arrays were washed with 1×PBST and bound antibodies were detected by incubating 408 with Cy3-conjugated goat anti-human IgG and Alexa Fluor 647-conjugated donkey 409 anti-human IgM (Jackson ImmunoResearch, PA, USA), which were diluted for 1: 1,000 410 in 1×PBST. The incubation was carried out at room temperature for 1 h. The microarrays 411 were then washed with 1×PBST and dried by centrifugation at room temperature and 412 scanned by LuxScan 10K-A (CapitalBio Corporation, Beijing, China) with the 413 parameters set as 95% laser power/ PMT 550 and 95% laser power/ PMT 480 for IgM 414 and IgG, respectively. The fluorescent intensity was extracted by GenePix Pro 6.0 415 416 software (Molecular Devices, CA, USA).

417

418 Data analysis of peptide microarray

For each spot, signal intensity was defined as the foreground subtracted by the background. The signal intensities of the triplicate spots for each peptide or protein were averaged. For the samples of Cohort 2 and 3, normalization among microarray slides were performed. For each slide, block #14 was incubated with the positive reference sample which was generated by pooling of 50 randomly selected sera from COVID-19

424 patients. For each slide, the data generated from the positive reference sample were 425 subjected to build a linear regression function, and the data from other samples were 426 subjected to linear normalization according to the function. Graphpad 6.0 was used to 427 generate ROC plots and calculated AUC values.

428

429 *ELISA*

430 Briefly, 96-well microplates with high binding polystyrene surface (Corning, New York, USA) were coated with 100 µL BSA conjugated peptide (S2-78) at 100 µg/mL and 431 incubated overnight at 4°C. The plates were washed once with PBST buffer (PBS buffer 432 with 0.1% Tween 20), and blocked with 3% BSA (bovine serum albumin) for 1 h at room 433 434 temperature, followed by one wash with PBST. The sera were diluted at 1:50 in PBST 435 buffer with 1% BSA, 1% FBS and 3% horse serum, 100 μ L of the preparation was loaded to each well, the incubation was carried out at 37° C for 1.5 h in 100 µL. After six washes 436 with PBST, the secondary antibody, *i.e.*, anti-human IgG-peroxidase (Sangon Biotech, 437 Shanghai, China) was diluted at 1:10000 and incubated at 37 ° C for 1 h, followed by 438 eight washes. Tetramethylbenzidine substrate (Sigma-Aldrich, Missouri, USA) was then 439 440 added and incubated for 20 min. Finally, 50 µL sulfuric acid (2 M) was added to stop the reaction. The optical density was read at 450 nm using a Behring EL311 ELISA 441 442 microplate reader (Dade Behring Marburg Gmbh, Berlin, Germany). The assays were repeated twice for each sample. 443

Abbreviations: AID: autoimmune diseases; AUC: area under curve; CI: confidence
interval; CoV: coronavirus; ELISA: enzyme linked immunosorbent assay; GMP: good
manufacturing practice; NAT: nucleic acid test; NPV: negative predictive value; PPV:
positive predictive value; ROC: receiver operating characteristic; SARS: severe acute
respiratory syndrome; URI: upper respiratory infections; WHO: world health
organization.

450 Acknowledgments: We thank Dr. Daniel M. Czajkowsky for critical reading and editing.

451 **Funding**: This work was partially supported by National Key Research and Development

452 Program of China Grant (No. 2016YFA0500600), Science and Technology Commission

of Shanghai Municipality (No. 19441911900), Interdisciplinary Program of Shanghai
Jiao Tong University (No. YG2020YQ10), National Natural Science Foundation of
China (No. 31900112, 21907065, 31970130 and 31670831).

456 Author contributions: S-C.T. developed the conceptual ideas and designed the study.

457 Z-Y.S., F.W., H-Y.H., Y-D.Z., X-S. L., Z-J.Y., H-M.S., J-X.W., L-Y.C., S-Q.L., P-F.P.,

- 458 and H.S. collected the sera samples. X-L.F., Y.L., D-Y.L., Q.L., Z-W.X., M-L. M., B.Z.,
- 459 H.C., C-Z.Y., J-B.X., X-N.W., Y-X.Z., H-N.Z., H-W.J., H.Q. Y-D.Z., X-S.L., Z-J.Y and
- 460 S-J.G. performed the experiments and analysis. S-C.T. and Y.L. wrote the manuscript
- 461 with suggestions from other authors.

462 Competing interests: Four relevant patents which have been applied in China
463 (application number: 202010413901.9, 202010415057.3, 202010415053.5 and
464 202010413911.2) are filed by Shanghai Jiao Tong University. S-C.T., Y.L., D-Y. L,
465 H-W.J., H-N.Z. and H.Q. are relevant to these patents. Other authors declare no conflicts
466 of interest.

467 Data and material availability: The peptide microarray data generated in this study has
468 been deposited to Protein Microarray Database (http://www.proteinmicroarray.cn) under
469 the accession number PMDE242 and PMDE244 Additional data related to this study may
470 be requested from the authors.

471

472 Supplementary Materials

473

474 Fig. S1. Evaluation of the significant peptides by Cohort 2 – other peptides.

475 Fig. S2. Performance of peptides and S1 for diagnosis in subgroups.

476 Fig. S3. Homology analysis of the significant peptides among SARS-CoV-2,

477 SARS-CoV, MERS-CoV and other four human coronaviruses.

- Fig. S4. Discrimination of related coronaviruses by combining S1 and peptides of
 Panel-A.
- 480 Table S1. Peptides of SARS-CoV-2 spike protein used in this study

483	Refer	ences
484		
485	1.	Zhou P, Yang X Lou, Wang XG, et al. A pneumonia outbreak associated with a
486		new coronavirus of probable bat origin. Nature [Internet]. 2020; 579: 270–3.
487		Available at: http://dx.doi.org/10.1038/s41586-020-2012-7
488	2.	Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
489		disease in China. Nature. 2020; 579: 265–9.
490	3.	Dong E, Du H, Gardner L. An interactive web-based dashboard to track
491		COVID-19 in real time. Lancet Infect Dis [Internet]. 2020; 20: 533-4. Available at:
492		http://dx.doi.org/10.1016/S1473-3099(20)30120-1
493	4.	Lee CYP, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19:
494		Epidemiologic Perspective on Surveillance and Control. Front Immunol. 2020; 11:
495		879.
496	5.	Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients
497		with COVID-19. Nat Med. 2020; 26: 845–8.
498	6.	Peeling RW, Wedderburn CJ, Garcia PJ, et al. Serology testing in the COVID-19
499		pandemic response. Lancet Infect Dis [Internet]. 2020; 3099: 30517–X. Available
500		at: http://www.ncbi.nlm.nih.gov/pubmed/32687805
501	7.	GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19
502		serological assays informs future diagnostics and exposure assessment. Nat
503		Commun. 2020; 11: 3436.
504	8.	Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and
505		SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev
506		Med Virol. 2020; 30: e2106.
507	9.	Jiang H, Li Y, Zhang H, et al. Global profiling of SARS-CoV-2 specific IgG/ IgM
508		responses of convalescents using a proteome microarray. Nat Commun. 2020; 11:
509		3581.
510	10.	Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of
511		the Science. Immunity. 2020; 52: 910–41.
512	11.	Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020; 395:
513	10	
514	12.	Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological
515	10	tests for covid-19: Systematic review and meta-analysis. BMJ. 2020; 370: m2516.
516	13.	Hicks J, Klumpp-Inomas C, Kalish H, et al. Serologic cross-reactivity of
517		SARS-CoV-2 with endemic and seasonal Betacoronaviruses. medRxiv [Internet].
518		2020; DOI: 10.1101/2020.06.22.2013/695. Available at:
519		nttps://www.medrxiv.org/content/10.1101/2020.06.22.2013/695v1%0Anttps://ww
520	14	Weng L Hey Y Wy X at al SADS CaV 2 protooms microarray for morning
521	14.	COVID 10 antihedy interestions at amine acid resolution, his Duiy [Internet], 2020.
522		COVID-19 antibody interactions at amino acid resolution. DioRXIV [Internet]. 2020; DOI: 10.1101/2020.02.26.004756. Available at:
525		DOI: $10.1101/2020.05.20.994/30$. Available al.
324 525	15	nup.//0101x1v.01g/content/early/2020/05/28/2020.05.20.994/30 Deh CM, Coriggima G, Wang P, et al. Two linear criterios on the SADS CoV 2
323 526	13.	roll Civi, Calissillo G, wang D, et al. 1 wo linear epitopes on the SAKS-COV-2 spike protein that eligit neutraliging antibodies in COVID 10 notionts. Not
320 527		Spike protein that encir neutransing antibodies in COVID-19 patients. Nat
321		Commun. 2020, 11. 2800.

 Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. medRxiv. 2020; DOI:10.1101/2020.05.11.20092528. I7. Li Y, Lai D, Zhang H, et al. Linear epitopes of SARS-CoV-2 spike protein el neutralizing antibodies in COVID-19 patients. medRxiv [Internet]. 2020; DOI:10.1101/2020.06.07.20125096. Available at: http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract 	icit
 DOI:10.1101/2020.05.11.20092528. I7. Li Y, Lai D, Zhang H, et al. Linear epitopes of SARS-CoV-2 spike protein el neutralizing antibodies in COVID-19 patients. medRxiv [Internet]. 2020; DOI:10.1101/2020.06.07.20125096. Available at: http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract 	icit
 Li Y, Lai D, Zhang H, et al. Linear epitopes of SARS-CoV-2 spike protein el neutralizing antibodies in COVID-19 patients. medRxiv [Internet]. 2020; DOI:10.1101/2020.06.07.20125096. Available at: http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract 	icit
 neutralizing antibodies in COVID-19 patients. medRxiv [Internet]. 2020; DOI:10.1101/2020.06.07.20125096. Available at: http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract 	
533 DOI:10.1101/2020.06.07.20125096. Available at: 534 http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract	
534 http://medrxiv.org/content/early/2020/06/09/2020.06.07.20125096.abstract	
554 http://incurry.org/content/curry/2020/00/07/2020.00.07.20125070.u05truct	
535 18 WHO WHO I aboratory testing for 2019 novel coronavirus (2019-nCoV) in	
536 suspected human cases 2020	
537 19 Xu X Sun I Nie S et al Seronrevalence of immunoglobulin M and G antibo	dies
537 17. Xu X, Sun J, We S, et al. Seroprevalence of minunoglobulin W and O antioc 528 against SARS CoV 2 in China Nat Med 2020: DOI: 10.1038/s/1501.020.0	0/0 6
530 20 Slot E Hogema BM Beusken CBEM Beimerink IH Molier M Karragat IE	9 49-0. [
539 20. Slot E, Hogema Divi, Reusken ODEW, Reinerlink JH, Moher W, Ranegat JH 540 Hard immunity is not a realistic avit stratagy during a COVID 10 authreak.	l. Tot
540 There minimum y is not a realistic exit strategy during a COVID-19 outbreak. If 541 D as 2020; DOI: 10.21202/rs 2 rs 25862/v1	nal
541 Res. 2020, DOI: 10.21205/15.5.15-25002/V1.	£
542 21. SIKOIA M, VOII BUIOW S, BIAIC FEC, Gecht M, Covino K, Hummer G. Map 0 542 SADS CoV 2 griles griteging not shielded by glycong his Driv [Intermet] 202	1
543 SARS-COV-2 spike epitopes not snielded by glycans. blokxiv [internet]. 202	0,
544 DOI. $10.1101/2020.0/.05.180825$. Available al.	
545 nup://biofxiv.org/content/early/2020/0//05/2020.0/.05.180825.abstract	tion in
546 22. Along F, wang A, He A, et al. Antibody Detection and Dynamic Characteris	tics in
54/ Patients with $COVID-19$. Clin Infect DIs. 2020; DOI: 10.1093/cld/claa461.	
548 23. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of	
stymptomatic SARS-Cov-2 infections. Nat Med. 2020; DOI:	
550 10.1038/s41591-020-0965-6.	<i>.</i> .
551 24. Let Q, Li Y, Hou H, et al. Antibody dynamics to SARS-CoV-2 in asymptoma	atic
552 COVID-19 infections. medRxiv. 2020; DOI: org/10.1101/2020.07.09.20149	9633.
553 25. Zhang X, Wu X, Wang D, et al. Proteome-wide analysis of	
554 differentially-expressed SARS-CoV-2 antibodies in early COVID-19 infectio	on.
555 medRxiv [Internet]. 2020; DOI:10.1101/2020.04.14.20064535. Available at:	
556 https://www.medrxiv.org/content/10.1101/2020.04.14.20064535v2?%253fcc	ollecti
557 on=	
558 26. Li Y, Ma M, Lei Q, et al. Linear epitope landscape of SARS-CoV-2 Spike pr	otein
constructed from 1,051 COVID-19 patients. medRxiv [Internet]. 2020;	
560 DOI:10.1101/2020.07.13.20152587. Available at:	
561 http://medrxiv.org/content/early/2020/07/14/2020.07.13.20152587.abstract	
562 27. Wan J, Xing S, Ding L, et al. Human IgG cell neutralizing monoclonal antibo	odies
563 block SARS- CoV-2 infection. Cell Rep. 2020; 32: 107918.	
28. Croop B, Zhang C, Lim Y, Gelfand RM, Han KY. Recent advancement of	
565 light-based single-molecule approaches for studying biomolecules. Wiley	
566 Interdiscip Rev Syst Biol Med. 2019; 11: e1445.	
567 29. McEachern F, Harvey E, Merle G. Emerging Technologies for the Electroche	emical
568 Detection of Bacteria. Biotechnol J. 2020; e2000140.	
569 30. Li Y, Li C-Q, Guo S-J, et al. Longitudinal serum autoantibody repertoire pro	filing
570 identifies surgery-associated biomarkers in lung adenocarcinoma. EBioMedi	cine.
571 2020; 53: 102674.	
572	
573	

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.



Figure 1. Peptides with strong IgG antibody responses were identified by Cohort 1. A. Representative images of peptide microarray profiled by sera from a COVID patient and a healthy control. IgG (green) and IgM (red) were detected simultaneously. **B.** Box plot of IgG antibody responses against S1 protein, N protein and some significant peptides for COVID-19 patient group (n=55) and control group (n=18) of Cohort 1. Each spot indicates one serum sample. Data are presented as box plots where the middle line is the mean value, and the upper and lower hinges are mean values \pm SD. AUC (area under curve) values are labeled for each peptide or protein on the top of the box plots. **C.** Averaged signal intensities of IgG antibody responses against the indicated peptides at different concentrations, *i.e.* 0.1, 0.3 and 0.9 mg/mL, both for COVID-19 patients (blue line) and control group (orange line).



Figure 2. Evaluation significant peptides by Cohort 2. **A.** ROCs (receiver operating curves) of the peptides or proteins for discrimination of the COVID-19 group (n=729) and the control group (n=542). The AUC values with 95% CI (confidential intervals) are provided for all the peptides and proteins. **B-E.** signal distributions of anti-S1 IgG (B), anti-S2-78 IgG (C), anti-S1-97 IgG (D) and anti-S1-93 (E) in COVID-19 patients (blue) and control groups (yellow). Sample size is indicated for each group. URI: upper respiratory infection, AID: patients with autoimmune diseases.



Figure 3. S2-78 IgG for diagnosis of COVID-19. A. Scatter plots of sera samples from COVID-19 (blue dots) and controls (orange triangle) for S1 IgG vs. S2-8 IgG. The grey lines indicate the cut-off values set as the optimal Youden index based on the ROC. The orange and blue numbers indicate the sample counts of control and patient on each quadrant, respectively. B. consistency between S1 protein and S2-78. The consistency values are provided with 95% CI. C. forest plot of sensitivities of S2-78 IgG among subgroups, i.e., age, gender, severity and outcome. The dots indicate the sensitivities while the error bars indicate the 95% CI. The exact values are also provided. P values were calculated with χ^2 test. D-E. Graph of positive rates of IgG or IgM against the S, N proteins or S2-78 versus days after symptom onset in 2,360 serum samples from 784 patients.



Figure 4. S2-78 IgG for diagnosis of asymptomatic patients. A-B. Levels of S1 IgG and S2-78 IgG in asymptomatic patient groups divided by positive or negative among three tests, i.e., NAT (nucleic acid test), SARS-CoV-2 virus specific IgG and IgM antibodies. The dashed lines indicate the cut-off values. The number of positive samples as well as the total number of samples of IgG+ (IgG positive) groups were presented for S1 IgG and S2-78 IgG. **C.** The consistency between S1 IgG and S2-78 IgG.



Figure 5. ELISA validation of S2-78 by Cohort 3. A. Correlation of the signals of S2-78 IgG response between peptide microarray and ELISA with Cohort 1 (n=31). B. Levels of S2-78 IgG in samples from COVID-19 patients either from Cohort 1 (n=31) or Cohort 3 (n=19) and healthy controls (n=50). C. ROC of S2-78 IgG for discrimination of 19 COVID-patients (Cohort 3) and 50 healthy controls.



Figure 6. Discrimination of related coronaviruses with combination of peptides.

A. Illustration of the strategy with combination of S2-78 IgG and S1-97 IgG based on the results of Cohort 2 (729 patients and 542 controls). For any given sample, the first step is to detect S2-78 IgG response. For the positive ones, the second step is to detect S1-97 IgG response. The blue numbers indicate the positive or negative rates for SARS-CoV-2 infections, while the green numbers indicated the assumed positive or negative rates for samples not belong the SARS-CoV-2 group. The last step summaries the overall sensitivities and specificities for different sample groups. **B**. Signals of Panel-A (S1-93, 97, 101 and 105 in COVID-19 patients and control groups. **C**. The corresponding ROC of Panel-A. **D**. The performance of the combination of S2-78 IgG and Panel-A.

		S	1	S2	2-78	
		Positive	Negative	Positive	Negative	
CC	VID-19	707	22	696	33	
С	ontrol	2	540	18	524	
Specificity (95% CI)		99.6% (98	99.6% (98.7-100%)		96.7% (94.8-98.0%)	
Sensitiv	vity (95% CI)	97% (95.5-98.1%)		95.5% (93.7-96.9%)		
Accuracy (95% CI)		98.1% (97.2-98.8%)		96% (94.8-97%)		
Prevalence						
עחס	0.04	91.0)%	54	.7%	
PPV	0.5	99.6%		97.5%		
	0.04	99.9	9%	99	.8%	
INF V	0.5	97.1	%	95	.6%	

 Table 2. The overall performance of S1 and S2-78 for diagnosis

PPV: positive predictive value NPV: negative predictive value

		Coh	ort 1		Cohort 2		Coho	ort 3	Cohort 4
Gr	oup	COVID-19	Control	COVID-19	Control-1	Control-2	COVID-19	Control	Asymptomatic patient ¹
Nur	nbers	55	18	729	469	73	19	50	63
St	age	Convales- cent	-	In hospital	-	-	Convales- cent	-	-
A	ge	41.5±14.9	50.4±12.5	61.4±14.5	53.7±20.6	N/A	53.9±13.2	46.7±20.2	44.9±16.5
Gender	Male	27	8	361	224	N/A	10	24	25
Gender	Female	28	10	368	245	N/A	9	26	38
Severity	Severe non- severe	0 55	-	393 336	-	-	0 19	-	-
Outcome	Discharge Death	55 0	-	679 50	-	-	19 0	-	-
Days at	fter onset	27.5±7.7	-	31.1±8.8	-	-	42.6±9.5	-	-
So	urce	Foshan 4th Hospital, Guangdon g	Ruijin Hospital, Shanghai	Tongji Hospital, Wuhan	Tongren Hospital, Shanghai Ruijin Hospital, Shanghai	National Institutes for Food and Drug Control, Beijing	The Fifth Affiliated Hospital Sun Yat-Sen University, Guangdong	Tongren Hospital, Shanghai	Tongji Hospital, Wuhan
Subty nun	pes and nbers	-	Healthy: 8; LC ⁴ : 8	This is a subgroup of a cohort of 784 cases with a total of 2,360 longitudinal sera.	Healthy: 92; URI ² : 104; AID ³ : 120; LC ⁴ : 41; Other diseases: 112	Negative reference samples	-	-	NAT+lgG-lgM-: 4; NAT+lgG+lgM-: 8; NAT-lgG+lgM+: 23; NAT-lgG+lgM-: 28

Table 1. Patients and controls involved in this study.

¹Asympotmatic patients: positive for NAT (nucleic acid test) or antibody (IgG or IgM) performed in hospital.

²URI: Upper respiratory infection

³AID: Autoimmune diseases

⁴LC: Lung cancer







Figure S1. Evaluation of the significant peptides by Cohort 2 – other peptides. Signal levels of the antibodies against the indicated peptides in COVID-19 patients (n=729), Healthy controls (n=92), upper respiratory infections (URI, n=104), patients with autoimmune diseases (AID, n=120), lung cancer patients (n=41), patients with other diseases (n=112) and negative reference samples (n=73) of Cohort 2.



Figure S2. Performance of peptides and S1 for diagnosis in subgroups. A. forest plot of sensitivities of S1 IgG in different subgroups, i.e., age, gender, severity and outcome. The dots indicate the sensitivities while the error bars indicate the 95% CI. The exact values are also provided. P values were calculated with $\chi 2$ test. **B.** Graph of positive rates of IgG antibodies against the indicated peptides versus days after symptom onset in 2,360 serum samples from 784 patients.

		31-93		01-01	
SARS-CoV-2	553	TESNKKFL-PFOO	564	SARS-CoV-2 577 RDPQTLEILDIT 588	
SARS-CoV	539	TPSSKRFQ-PFQQ	550	SARS-CoV 563 RDPKTSEILDIS 574	
MERS-CoV	618	QNCTAVGV-RQQR	629	MERS-CoV 643 SDDGNYYCLR 652	
HCoV-0C43	636	VEVNATYYNSWQN	648	HCoV-OC43 661 RDYIINRTFMIR 672	
HCoV-HKU1	636	KEVSAVYYNSWQN	648	HCoV-HKU1 661 KDFVTNKTYNIF 672	
HCoV-NL63	642	RS SN QSLAGG	651	HCoV-NL63 665 KNVSTGNIFIVT 676	
HCoV-229E	458	RI SN DTFLNG	467	HCoV-229E 481 KDVTNGTIYSIT 492	
		S1-101		S1-105	
SARS-CoV-2	601	GTNTSNOVAVLY	612	SARS-CoV-2 625 HADOLTPTWRVY 63	6
SARS-CoV	587	GTNASSEVAVLY	598	SARS-CoV 611 HADOLTPAWRIY 62	2
MERS-CoV	665	KETKTH A TLF	674	MERS-CoV 686 SQYSRSTRSMLKRR 69)7
HCoV-0C43	685	ANSSEPALLF	694	HCoV-0C43 706 LTR QL Q P INYFD 71	7
HCoV-HKU1	685	QNASSLALLY	694	HCoV-HKU1 706 SLATQ 71	0
HCoV-NL63	689	Q	689	HCoV-NL63 701 SRYG L QNLLQLP 71	2
HCoV-229E	505	Q	505	HCoV-229E 517 TSYGFSNVVEMP 52	28
		S1-111		S2-78	
SARS-CoV-2	661	ECDIPIGAGICA	672	SARS-CoV-2 1148 FKEELDKYFKNH 1159	
SARS-CoV	647	ECDIPIGAGICA	658	SARS-CoV 1130 FKEELDKYFKNH 1141	
MERS-CoV	726	D C KL PLG QS LCA	737	MERS-CoV 1231 FQDELDEFFKNV 1242	
HCoV-0C43	737	TCDLTVGSGYCV	748	HCoV-0C43 1233 FKEELDQWFKNQ 1244	
HCoV-HKU1	685	SCALRMGSGFCV	694	HCoV-HKU1 1234 FESELSHWFKNQ 1245	
HCoV-NL63	727	AVMTYSNF GICA	738	HCoV-NL63 1217 VNKTLQEFAQNL 1228	
HCoV-229E	543	AVLTYSSF G V CA	554	HCoV-229E 1033 VNKTLQELSYKL 1044	
		S2-22		\$2-97	
SARS-CoV-2	812	PSKRSFIEDLLF	823	SARS-CoV-2 1262 EPVLKGVKLHYT 1273	
SARS-CoV	794	PTKRSFIEDLLF	805	SARS-CoV ¹²⁴⁴ EPVLKGVKLHYT ¹²⁵⁵	
MERS-CoV	884	RSARSAIEDLLF	895	MERS-CoV 1346 EPHKVHVH 1353	
HCoV-0C43	900	ASSRSAIEDLLF	911	HCoV-OC43 1343 ELVIK-TSHDD- 1353	
HCoV-HKU1	902	-SSRSFFEDLLF	912	HCoV-HKU1 ¹³⁴⁷ DFVIK-TSHDD- ¹³⁵⁶	
HCoV-NL63	867	IAG RS AL EDLLF	878	HCoV-NL63 1352 _{VHVQ} 1356	
HCoV-229E	683	VAG RS A IEDILF	694	HCoV-229E 1166 IHIO 1170	

C1 07

04 00

Figure S3. Homology analysis of the significant peptides among SARS-CoV-2, SARS-CoV, MERS-CoV and other four human coronaviruses. The line for each position indicates the gap. The bold letters indicate the positions with the same amino acids as that of SARS-CoV-2. The homology analysis was performed by an online tool called Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/).



Figure S4. Discrimination of related coronaviruses by combining S1 and peptides of Panel-A. A. ROC of S1-97 IgG based on the results of Cohort 2. **B.** The combination of S1 IgG and Panel-A based on the results of Cohort 2 (729 patients and 542 controls).

NO.	Peptide ID	Sart Position	Amino acid sequence	End Position	Note
1	S1-1	1	MFVFLVLLPLVS	12	N/A
2	S1-2	7	LLPLVSSQCVNL	18	
3	S1-3	13	SQCVNLTTRTQL	24	N/A
4	S1-4	19	TTRTQLPPAYTN	30	
5	S1-5	25	PPAYTNSFTRGV	36	
6	S1-6	31	SFTRGVYYPDKV	42	
7	S1-7	37	YYPDKVFRSSVL	48	
8	S1-8	43	FRSSVLHSTQDL	54	
9	S1-9	49	HSTQDLFLPFFS	60	
10	S1-10	55	FLPFFSNVTWFH	66	N/A
11	51-11	01	NVIVEHAIHVSG	72	
12	51-12	0/		78	
13	51-13	73		04	
14	S1-14 S1 15	19		90	
15	S1-15 S1-16	00		90 102	
10	S1-10 S1-17	97	KSNIIRGWIEGT	102	
18	S1-18	103	GWIEGTTI DSKT	114	
19	S1-19	109	TLDSKTOSUUV	120	
20	S1-20	115	QSLLIVNNATNV	126	
21	S1-21	121	NNATNVVIKVCE	132	
22	S1-22	127	VIKVCEFQFCND	138	
23	S1-23	133	FQFCNDPFLGVY	144	
24	S1-24	139	PFLGVYYHKNNK	150	
25	S1-25	145	YHKNNKSWMESE	156	
26	S1-26	151	SWMESEFRVYSS	162	
27	S1-27	157	FRVYSSANNCTF	168	
28	S1-28	163	ANNCTFEYVSQP	174	
29	S1-29	169	EYVSQPFLMDLE	180	
30	S1-30	175	FLMDLEGKQGNF	186	
31	S1-31	181	GKQGNFKNLREF	192	
32	S1-32	187	KNLREFVFKNID	198	N/A
33	S1-33	193	VFKNIDGYFKIY	204	N/A
34	S1-34	199	GYFKIYSKHTPI	210	
35	S1-35	205	SKHTPINLVRDL	216	N/A
36	S1-36	211	NLVRDLPQGFSA	222	
37	S1-37	217	PQGFSALEPLVD	228	N/A
38	S1-38	223	LEPLVDLPIGIN	234	
39	S1-39	229	LPIGINITRFQT	240	
40	S1-40	235	ITRFQTLLALHR	246	N/A
41	S1-41	241	LLALHRSYLTPG	252	
42	S1-42	247	SYLIPGDSSSGW	258	
43	S1-43	253	DSSSGWTAGAAA	264	
44	S1-44	259		270	
45	51-45	265		276	N1/ A
40	51-40	2/1		202	N/A
41 10	01-4/ 01 10	211		∠00 204	
40 40	01-40 01 10	200 220		294 200	
49 50	01-49 01_50	209 205	V DOALDELOEIN DI SETKATI KSE	300	
50	S1-30 S1_51	290		212	
52	Q1_57	301		312	
52	S1-52	313		324	
54	<u>S1-53</u>	310		330	
55	S1-55	325	SIVREPNITNI C	336	
56	S1-56	331	NITNI CPEGEVE	342	
57	S1-57	337	PEGEVENATREA	348	
58	S1-58	343	NATREASVYAWN	354	
59	S1-59	349	SVYAWNRKRISN	360	
60	S1-60	355	RKRISNCVADYS	366	
61	S1-61	361	CVADYSVLYNSA	372	N/A
62	S1-62	367	VLYNSASFSTFK	378	
63	S1-63	373	SFSTFKCYGVSP	384	
64	S1-64	379	CYGVSPTKLNDL	390	

65	S1-65	385	TKLNDLCFTNVY	396	
66	S1-66	391	CFTNVYADSFVI	402	
67	S1-67	397	ADSFVIRGDEVR	408	
68	S1-68	403	RGDEVRQIAPGQ	414	
69	S1-69	409	QIAPGQTGKIAD	420	
70	S1-70	415	TGKIADYNYKLP	426	
71	S1-71	421	YNYKLPDDFTGC	432	
72	S1-72	427	DDFTGCVIAWNS	438	
73	S1-73	433	VIAWNSNNLDSK	444	
74	S1-74	439	NNI DSKVGGNYN	450	
75	S1-75	445	VGGNYNYI YRI F	456	N/A
76	S1-76	451	YI YRI FRKSNI K	462	
77	S1-77	457	RKSNI KPEERDI	468	
78	S1-78	463	PEERDISTEIYO	400	
70	S1-79	469	STEIYOAGSTPC	480	
80	S1-80	400	AGSTPCNGVEGE	486	
81	S1-81	481	NGVEGENCYEPI	400	
82	S1 92	401		408	
92	S1-02 S1 93	407		490	
84	S1-05 S1 84	493		510	
04	S1-04 S1 05	499		510	
00	51-00	505	A CELLIADA	510	
00	S1-00	511	VVLSFELLMAPA	522	
٥ <i>٢</i>	51-87	500		528	
88	51-88	523		534	
89	51-89	529	KSTNLVKNKCVN	540	
90	S1-90	535		546	
91	S1-91	541		552	
92	S1-92	547	IGIGVLIESNKK	558	
93	S1-93	553	TESNKKFLPFQQ	564	
94	S1-94	559	FLPFQQFGRDIA	570	
95	S1-95	565	FGRDIADTIDAV	576	
96	S1-96	571	DIIDAVRDPQIL	582	
97	S1-97	577	RDPQTLEILDIT	588	
98	S1-98	583	EILDITPCSFGG	594	
99	S1-99	589	PCSFGGVSVITP	600	
100	S1-100	595	VSVITPGTNTSN	606	
101	S1-101	601	GTNTSNQVAVLY	612	
102	S1-102	607	QVAVLYQDVNCT	618	
103	S1-103	613	QDVNCTEVPVAI	624	
104	S1-104	619	EVPVAIHADQLT	630	
105	S1-105	625	HADQLTPTWRVY	636	
106	S1-106	631	PTWRVYSTGSNV	642	
107	S1-107	637	STGSNVFQTRAG	648	N/A
108	S1-108	643	FQTRAGCLIGAE	654	
109	S1-109	649	CLIGAEHVNNSY	660	
110	S1-110	655	HVNNSYECDIPI	666	
111	S1-111	661	ECDIPIGAGICA	672	
112	S1-112	667	GAGICASYQTQT	678	
113	S1-113	673	SYQTQTNSPRRA	684	
114	S1-114	679	NSPRRARGGGGS	685	
115	S2-1	686	SVASQSIIAYTM	697	N/A
116	S2-2	692	IIAYTMSLGAEN	703	N/A
117	S2-3	698	SLGAENSVAYSN	709	
118	S2-4	704	SVAYSNNSIAIP	715	
119	S2-5	710	NSIAIPTNFTIS	721	
120	S2-6	716	TNFTISVTTEIL	727	
121	S2-7	722	VTTEILPVSMTK	733	
122	S2-8	728	PVSMTKTSVDCT	739	
123	S2-9	734	TSVDCTMYICGD	745	
124	S2-10	740	MYICGDSTECSN	751	
125	S2-11	746	STECSNLLLQYG	757	
	02-11				
126	S2-12	752	LLLQYGSFCTQL	763	
126 127	S2-12 S2-13	752 758	LLLQYGSFCTQL SFCTQLNRALTG	763 769	N/A
126 127 128	S2-11 S2-12 S2-13 S2-14	752 758 764	LLLQYGSFCTQL SFCTQLNRALTG NRALTGIAVEQD	763 769 775	N/A
126 127 128 129	S2-12 S2-13 S2-14 S2-15	752 758 764 770	LLLQYGSFCTQL SFCTQLNRALTG NRALTGIAVEQD IAVEQDKNTQEV	763 769 775 781	N/A
126 127 128 129 130	S2-12 S2-13 S2-14 S2-15 S2-16	752 758 764 770 776	LLLQYGSFCTQL SFCTQLNRALTG NRALTGIAVEQD IAVEQDKNTQEV KNTQEVFAQVKQ	763 769 775 781 787	N/A

132	S2-18	788	IYKTPPIKDFGG	799	
133	S2-19	794	IKDEGGENESOI	805	
100	02 10	000		000	
134	52-20	800	FNFSQILPDPSK	811	
135	S2-21	806	LPDPSKPSKRSF	817	
136	S2-22	812	PSKRSFIEDLLE	823	
100	02 22	010		020	
137	52-23	818	IEDLLENKVILA	829	
138	S2-24	824	NKVTLADAGFIK	835	
139	S2-25	830	DAGEIKQYGDCI	841	
140	02 20	000		0.47	
140	52-20	830	QYGDCLGDIAAR	847	
141	S2-27	842	GDIAARDLICAQ	853	
142	S2-28	848	DLICAQKENGLT	859	
140	C2 20	054		005	
143	32-29	004	KFINGLIVLFFLL	005	
144	S2-30	860	VLPPLLTDEMIA	871	
145	S2-31	866	TDEMIAQYTSAL	877	
1/6	60.30	872	OVISALLACTIT	883	
140	32-32	072	QTIGALLAGTI	000	
147	S2-33	878	LAGTITSGWTFG	889	
148	S2-34	884	SGWTFGAGAALQ	895	
140	S2 35	800		001	
149	32-35	090		901	
150	S2-36	896	IPFAMQMAYRFN	907	
151	S2-37	902	MAYRFNGIGVTQ	913	
152	\$2-38	908		Q1Q	
152	32-30	300		313	
153	S2-39	914	NVLYENQKLIAN	925	
154	S2-40	920	QKLIANQFNSAI	931	
155	S2-41	926	OENSAIGKIODS	937	
155	02-41	020		040	
156	52-42	932	GRIQUSESSIAS	943	
157	S2-43	938	LSSTASALGKLQ	949	
158	S2-44	944		955	
100	02 45	050		000	
159	52-45	950	DVVNQNAQALNT	901	
160	S2-46	956	AQALNTLVKQLS	967	
161	S2-47	962	I VKOLSSNEGAL	973	
160	CO 40	069		070	
102	52-40	900	SINFGAISSVLIND	979	
163	S2-49	974	SSVLNDILSRLD	985	
164	S2-50	980	ILSRLDKVEAEV	991	
165	S2 51	086		007	
105	32-31	900	RVEAEVQIDRLI	997	
166	S2-52	992	QIDRLITGRLQS	1003	
167	S2-53	998	TGRLQSLQTYVT	1009	
168	S2-54	1004		1015	
100	02-04	1004		1015	
169	S2-55	1010	QQLIRAAEIRAS	1021	
170	S2-56	1016	AEIRASANLAAT	1027	
171	S2-57	1022	ANI AATKMSECV	1033	
17.1	02 07	1022		1000	
172	52-58	1028	KMSECVLGQSKR	1039	
173	S2-59	1034	LGQSKRVDFCGK	1045	
174	S2-60	1040	VDECGKGYHLMS	1051	
175	C2 61	1046		1057	
1/5	52-01	1040	GTHLMSFPQSAP	1057	
176	S2-62	1052	FPQSAPHGVVFL	1063	
177	S2-63	1058	HGVVFLHVTYVP	1069	
179	\$2.64	1064		1075	
170	00.07	40-0		1070	
179	52-65	1070	AQEKNELIAPAI	1081	
180	S2-66	1076	TTAPAICHDGKA	1087	
181	S2-67	1082	CHDGKAHEPREG	1093	
400	60.60	1000		1000	
182	52-00	1088	TIFFKEGVFVSNG	1099	
183	S2-69	1094	VFVSNGTHWFVT	1105	
184	S2-70	1100	THWFVTQRNFYE	1111	
195	C0 71	1106		1117	
105	32-71	1100	QRINFTEPQITT	1117	
186	S2-72	1112	PQIITTDNTFVS	1123	
187	S2-73	1118	DNTFVSGNCDVV	1129	
188	S2_7/	112/	GNCDV//GIVNN	1135	NI/A
100	02-74	1124		1155	11/71
189	S2-75	1130	IGIVNNTVYDPL	1141	
190	S2-76	1136	TVYDPLQPELDS	1147	
101	S2-77	1142		1153	
101	02-11	1172		1100	
192	S2-78	1148	FKEELDKYFKNH	1159	
193	S2-79	1154	KYFKNHTSPDVD	1165	
194	S2-80	1160	TSPDVDI GDISC	1171	
10-	02.00	4400		4477	
195	52-01	0011	LGDISGINASVV	1177	
196	S2-82	1172	INASVVNIQKEI	1183	
197	S2-83	1178	NIQKEIDRLNFV	1189	
100	CO 04	1101		1100	
190	32-04	1104	DISLINEVANNLINE	1195	

199	S2-85	1190	AKNLNESLIDLQ	1201	
200	S2-86	1196	SLIDLQELGKYE	1207	
201	S2-87	1202	ELGKYEQYIKWP	1213	
202	S2-88	1208	QYIKWPWYIWLG	1219	
203	S2-89	1214	WYIWLGFIAGLI	1225	N/A
204	S2-90	1220	FIAGLIAIVMVT	1231	N/A
205	S2-91	1226	AIVMVTIMLCCM	1237	N/A
206	S2-92	1232	IMLCCMTSCCSC	1243	N/A
207	S2-93	1238	TSCCSCLKGCCS	1249	
208	S2-94	1244	LKGCCSCGSCCK	1255	N/A
209	S2-95	1250	CGSCCKFDEDDS	1261	
210	S2-96	1256	FDEDDSEPVLKG	1267	
211	S2-97	1262	EPVLKGVKLHYT	1273	